FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2783197724> ?p ?o ?g. }

• W2783197724 endingPage "230" @default.
• W2783197724 startingPage "215" @default.
• W2783197724 abstract "Pro-carboxypeptidase B2 (pro-CPB2) or thrombin-activatable fibrinolysis inhibitor (TAFI) is a glycoprotein encoded by the CPB2 gene and deregulated in several cancer types, including breast cancer. Thrombin binding to thrombomodulin (TM), encoded by THBD, is important for TAFI activation. CPB2 gene expression is influenced by genetic polymorphism and cytokines such as interleukin 10 (IL-10). Our previous results showed that tumor infiltrating monocytes/macrophages (CD14+/CD16+) isolated from inflammatory breast cancer (IBC) patients’ secrete high levels of IL-10. The aim of the present study is to test genetic polymorphism and expression of CPB2 in healthy breast tissues and carcinoma tissues of non-IBC and IBC patients. Furthermore, to investigate whether IL-10 modulates the expression of CPB2 and THBD in vivo and in-vitro. We tested CPB2 Thr325Ile polymorphism using restriction fragment length polymorphism, (RFLP) technique in healthy and carcinoma breast tissues. The mRNA expression of CPB2, THBD and IL10 were assessed by RT-qPCR. Infiltration of CD14+ cells was assessed by immunohistochemistry. In addition, we investigated the correlation between infiltration of CD14+ cells and expression of IL10 and CPB2. Furthermore, we correlated IL10 expression with the expression of both CPB2 and THBD in breast carcinoma tissues. Finally, we validated the role of recombinant IL-10 in regulating the expression of CPB2 and THBD using different breast cancer cell lines. Our results showed that CPB2 genotypes carrying the high-risk allele [Thr/Ile (CT) and Ile/Ile (TT)] were more frequent in both IBC and non-IBC patients compared to control group. CPB2 genotypes did not show any statistical correlation with CPB2 mRNA expression levels or patients’ clinical pathological properties. Interestingly, CPB2 and IL10 expression were significantly higher and positively correlated with the incidence of CD14+ cells in carcinoma tissues of IBC as compared to non-IBC. On the other hand, THBD expression was significantly lower in IBC carcinoma versus non-IBC tissues. Based on molecular subtypes, CPB2 and IL10 expression were significantly higher in triple negative (TN) as compared to hormonal positive (HP) carcinoma tissues of IBC. Moreover, CPB2 expression was positively correlated with presence of lymphovascular invasion and the expression of IL10 in carcinoma tissues of IBC patients. Furthermore, recombinant human IL-10 stimulated CPB2 expression in SUM-149 (IBC cell line) but not in MDA-MB-231 (non-IBC cell line), while there was no significant effect THBD expression. In conclusion, carcinoma tissues of IBC patients are characterized by higher expression of CPB2 and lower expression of THBD. Moreover, CPB2 positively correlates with IL10 mRNA expression, incidence of CD14+ cells and lymphovascular invasion in IBC patients. IL-10 stimulated CPB2 expression in TN-IBC cell line suggests a relevant role of CPB2 in the aggressive phenotype of IBC." @default.
• W2783197724 created "2018-01-26" @default.
• W2783197724 creator A5001789214 @default.
• W2783197724 creator A5004439929 @default.
• W2783197724 creator A5010074250 @default.
• W2783197724 creator A5018629496 @default.
• W2783197724 creator A5027509318 @default.
• W2783197724 creator A5031654355 @default.
• W2783197724 creator A5044629444 @default.
• W2783197724 creator A5085532598 @default.
• W2783197724 creator A5091132123 @default.
• W2783197724 date "2018-03-01" @default.
• W2783197724 modified "2023-10-17" @default.
• W2783197724 title "IL-10 correlates with the expression of carboxypeptidase B2 and lymphovascular invasion in inflammatory breast cancer: The potential role of tumor infiltrated macrophages" @default.
• W2783197724 cites W1444174644 @default.
• W2783197724 cites W1518308640 @default.
• W2783197724 cites W183114306 @default.
• W2783197724 cites W1921131085 @default.
• W2783197724 cites W1954576125 @default.
• W2783197724 cites W1971144980 @default.
• W2783197724 cites W1980188722 @default.
• W2783197724 cites W1985935936 @default.
• W2783197724 cites W1989685020 @default.
• W2783197724 cites W1994314071 @default.
• W2783197724 cites W2005012237 @default.
• W2783197724 cites W2006720521 @default.
• W2783197724 cites W2007684745 @default.
• W2783197724 cites W2008623356 @default.
• W2783197724 cites W2011815215 @default.
• W2783197724 cites W2012165453 @default.
• W2783197724 cites W2015565459 @default.
• W2783197724 cites W2015652503 @default.
• W2783197724 cites W2017456649 @default.
• W2783197724 cites W2017662235 @default.
• W2783197724 cites W2019399234 @default.
• W2783197724 cites W2019713252 @default.
• W2783197724 cites W2019715374 @default.
• W2783197724 cites W2024789639 @default.
• W2783197724 cites W2026484845 @default.
• W2783197724 cites W2034600376 @default.
• W2783197724 cites W2038148640 @default.
• W2783197724 cites W2041702904 @default.
• W2783197724 cites W2045303671 @default.
• W2783197724 cites W2062801646 @default.
• W2783197724 cites W2079175463 @default.
• W2783197724 cites W2080218780 @default.
• W2783197724 cites W2093389482 @default.
• W2783197724 cites W2093997298 @default.
• W2783197724 cites W2102379101 @default.
• W2783197724 cites W2106352950 @default.
• W2783197724 cites W2113137803 @default.
• W2783197724 cites W2118785471 @default.
• W2783197724 cites W2127536162 @default.
• W2783197724 cites W2132265884 @default.
• W2783197724 cites W2143613937 @default.
• W2783197724 cites W2154903114 @default.
• W2783197724 cites W2160859576 @default.
• W2783197724 cites W2165388517 @default.
• W2783197724 cites W2168825967 @default.
• W2783197724 cites W2312481031 @default.
• W2783197724 cites W2314999790 @default.
• W2783197724 cites W2403503400 @default.
• W2783197724 cites W2465764254 @default.
• W2783197724 cites W2562766189 @default.
• W2783197724 cites W2593709873 @default.
• W2783197724 cites W2605561567 @default.
• W2783197724 cites W2626249377 @default.
• W2783197724 cites W2743591487 @default.
• W2783197724 cites W4235382952 @default.
• W2783197724 cites W4239540578 @default.
• W2783197724 doi "https://doi.org/10.1016/j.currproblcancer.2018.01.009" @default.
• W2783197724 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29459177" @default.
• W2783197724 hasPublicationYear "2018" @default.
• W2783197724 type Work @default.
• W2783197724 sameAs 2783197724 @default.
• W2783197724 citedByCount "15" @default.
• W2783197724 countsByYear W27831977242019 @default.
• W2783197724 countsByYear W27831977242020 @default.
• W2783197724 countsByYear W27831977242021 @default.
• W2783197724 countsByYear W27831977242022 @default.
• W2783197724 crossrefType "journal-article" @default.
• W2783197724 hasAuthorship W2783197724A5001789214 @default.
• W2783197724 hasAuthorship W2783197724A5004439929 @default.
• W2783197724 hasAuthorship W2783197724A5010074250 @default.
• W2783197724 hasAuthorship W2783197724A5018629496 @default.
• W2783197724 hasAuthorship W2783197724A5027509318 @default.
• W2783197724 hasAuthorship W2783197724A5031654355 @default.
• W2783197724 hasAuthorship W2783197724A5044629444 @default.
• W2783197724 hasAuthorship W2783197724A5085532598 @default.
• W2783197724 hasAuthorship W2783197724A5091132123 @default.
• W2783197724 hasBestOaLocation W27831977242 @default.
• W2783197724 hasConcept C104317684 @default.
• W2783197724 hasConcept C121608353 @default.
• W2783197724 hasConcept C126322002 @default.
• W2783197724 hasConcept C142724271 @default.
• W2783197724 hasConcept C150194340 @default.
• W2783197724 hasConcept C187316574 @default.
• W2783197724 hasConcept C203014093 @default.

• next